CA2546729A1 - Phenyl-furan compounds as vitamin d receptor modulators - Google Patents
Phenyl-furan compounds as vitamin d receptor modulators Download PDFInfo
- Publication number
- CA2546729A1 CA2546729A1 CA002546729A CA2546729A CA2546729A1 CA 2546729 A1 CA2546729 A1 CA 2546729A1 CA 002546729 A CA002546729 A CA 002546729A CA 2546729 A CA2546729 A CA 2546729A CA 2546729 A1 CA2546729 A1 CA 2546729A1
- Authority
- CA
- Canada
- Prior art keywords
- hydroxy
- compound
- ethyl
- treating
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000009310 vitamin D receptors Human genes 0.000 title claims abstract 8
- 108050000156 vitamin D receptors Proteins 0.000 title claims abstract 8
- 150000005353 phenylfurans Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract 16
- 201000004681 Psoriasis Diseases 0.000 claims abstract 6
- -1 1-hydroxy-2,2-dimethylpropyl Chemical group 0.000 claims 25
- 238000000034 method Methods 0.000 claims 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 6
- 239000004615 ingredient Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 6
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 208000001132 Osteoporosis Diseases 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000001575 pathological effect Effects 0.000 claims 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 3
- 241000219198 Brassica Species 0.000 claims 3
- 235000003351 Brassica cretica Nutrition 0.000 claims 3
- 235000003343 Brassica rupestris Nutrition 0.000 claims 3
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 235000010460 mustard Nutrition 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 210000004927 skin cell Anatomy 0.000 claims 3
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 2
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000010392 Bone Fractures Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 206010040954 Skin wrinkling Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 208000009621 actinic keratosis Diseases 0.000 claims 2
- 231100000360 alopecia Toxicity 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 230000005779 cell damage Effects 0.000 claims 2
- 208000037887 cell injury Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002500 effect on skin Effects 0.000 claims 2
- 230000005484 gravity Effects 0.000 claims 2
- 230000035876 healing Effects 0.000 claims 2
- 230000036571 hydration Effects 0.000 claims 2
- 238000006703 hydration reaction Methods 0.000 claims 2
- 230000000148 hypercalcaemia Effects 0.000 claims 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 208000005368 osteomalacia Diseases 0.000 claims 2
- 229940075993 receptor modulator Drugs 0.000 claims 2
- 201000006409 renal osteodystrophy Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- 210000002374 sebum Anatomy 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 230000037393 skin firmness Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 230000037303 wrinkles Effects 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 102000055006 Calcitonin Human genes 0.000 claims 1
- 108060001064 Calcitonin Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 229940030486 androgens Drugs 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 1
- 229960004015 calcitonin Drugs 0.000 claims 1
- 229940069978 calcium supplement Drugs 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000011280 coal tar Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 150000004673 fluoride salts Chemical class 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 239000003451 thiazide diuretic agent Substances 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 abstract 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 235000020964 calcitriol Nutrition 0.000 abstract 1
- 239000011612 calcitriol Substances 0.000 abstract 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000000121 hypercalcemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Liquid Crystal Substances (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52401503P | 2003-11-20 | 2003-11-20 | |
| US60/524,015 | 2003-11-20 | ||
| PCT/US2004/035527 WO2005051936A1 (en) | 2003-11-20 | 2004-11-16 | Phenyl-furan compounds as vitamin d receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2546729A1 true CA2546729A1 (en) | 2005-06-09 |
Family
ID=34632855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002546729A Abandoned CA2546729A1 (en) | 2003-11-20 | 2004-11-16 | Phenyl-furan compounds as vitamin d receptor modulators |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7468449B2 (https=) |
| EP (1) | EP1692123B1 (https=) |
| JP (1) | JP4750713B2 (https=) |
| AT (1) | ATE396982T1 (https=) |
| CA (1) | CA2546729A1 (https=) |
| DE (1) | DE602004014188D1 (https=) |
| ES (1) | ES2307069T3 (https=) |
| WO (1) | WO2005051936A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1511740T1 (sl) * | 2002-05-29 | 2009-12-31 | Lilly Co Eli | Modulatorji vitamin d receptorja tipa fenil-tiofen |
| DE60326082D1 (de) | 2002-11-22 | 2009-03-19 | Lilly Co Eli | Modulatoren von vitamin d rezeptoren |
| CA2544857A1 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
| ES2291981T3 (es) * | 2003-11-20 | 2008-03-01 | Eli Lilly And Company | Moduladores del receptor de la vitamina d. |
| US7595345B2 (en) | 2003-11-20 | 2009-09-29 | Eli Lilly And Company | Vitamin D receptor modulators |
| WO2005051936A1 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Phenyl-furan compounds as vitamin d receptor modulators |
| WO2005051898A2 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
| DK1836151T3 (da) * | 2004-12-21 | 2009-06-02 | Lilly Co Eli | D-vitamin-receptormodulatorer |
| CA2589667A1 (en) * | 2004-12-21 | 2006-06-29 | Eli Lilly And Company | Vitamin d receptor modulators |
| US9370527B2 (en) | 2012-12-28 | 2016-06-21 | The Regents Of The University Of Michigan | Amelioration of intestinal fibrosis and treatment of Crohn's disease |
| CN103193695B (zh) * | 2013-04-22 | 2015-08-05 | 中国药科大学 | 3-苯基-3-吡咯基戊烷类衍生物及其医药用途 |
| WO2017079718A1 (en) | 2015-11-06 | 2017-05-11 | Regents Of The University Of Minnesota | Methods of forming aromatic containing compounds |
| US11236057B2 (en) | 2015-11-06 | 2022-02-01 | Regents Of The University Of Minnesota | Aromatic surfactants |
| CN106908559B (zh) * | 2015-12-23 | 2020-08-11 | 重庆华邦胜凯制药有限公司 | 卡泊三醇中间体l及相关杂质的分离与测定方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4282246A (en) * | 1980-03-07 | 1981-08-04 | Pfizer Inc. | Antidiabetic furancarboxylic and thiphenecarboxylic acids |
| US6218430B1 (en) * | 1998-08-24 | 2001-04-17 | Ligand Pharmaceuticals Incorporated | Vitamin D3 mimics |
| SI1511740T1 (sl) | 2002-05-29 | 2009-12-31 | Lilly Co Eli | Modulatorji vitamin d receptorja tipa fenil-tiofen |
| DE10229456A1 (de) * | 2002-07-01 | 2004-02-05 | Wank, Rudolf, Prof. Dr.med. | Verwendung von Dopamin-Rezeptor-Agonisten zur Behandlung von Hautgeschwülsten und Warzen |
| EP1587906A2 (en) | 2003-01-10 | 2005-10-26 | Eli Lilly And Company | Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators |
| WO2004063348A2 (en) | 2003-01-10 | 2004-07-29 | Eli Lilly And Company | Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators |
| ES2291981T3 (es) * | 2003-11-20 | 2008-03-01 | Eli Lilly And Company | Moduladores del receptor de la vitamina d. |
| US7595345B2 (en) | 2003-11-20 | 2009-09-29 | Eli Lilly And Company | Vitamin D receptor modulators |
| CA2544857A1 (en) * | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
| WO2005051936A1 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Phenyl-furan compounds as vitamin d receptor modulators |
| WO2005051898A2 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
-
2004
- 2004-11-16 WO PCT/US2004/035527 patent/WO2005051936A1/en not_active Ceased
- 2004-11-16 EP EP04810027A patent/EP1692123B1/en not_active Expired - Lifetime
- 2004-11-16 US US10/578,991 patent/US7468449B2/en not_active Expired - Fee Related
- 2004-11-16 ES ES04810027T patent/ES2307069T3/es not_active Expired - Lifetime
- 2004-11-16 JP JP2006541190A patent/JP4750713B2/ja not_active Expired - Fee Related
- 2004-11-16 CA CA002546729A patent/CA2546729A1/en not_active Abandoned
- 2004-11-16 AT AT04810027T patent/ATE396982T1/de not_active IP Right Cessation
- 2004-11-16 DE DE602004014188T patent/DE602004014188D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1692123A1 (en) | 2006-08-23 |
| EP1692123B1 (en) | 2008-05-28 |
| WO2005051936A1 (en) | 2005-06-09 |
| DE602004014188D1 (de) | 2008-07-10 |
| US7468449B2 (en) | 2008-12-23 |
| JP2007512326A (ja) | 2007-05-17 |
| ES2307069T3 (es) | 2008-11-16 |
| JP4750713B2 (ja) | 2011-08-17 |
| ATE396982T1 (de) | 2008-06-15 |
| US20070105951A1 (en) | 2007-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2546729A1 (en) | Phenyl-furan compounds as vitamin d receptor modulators | |
| DE69400469T2 (de) | Vitamin-D-Derivate und Verfahren zur Herstellung dieser Verbindungen | |
| DE69105981T2 (de) | Neue vitamin d derivate. | |
| DE69807852T2 (de) | 2-alkyliden-19-nor-vitamin d-verbindungen | |
| AU2007234717B2 (en) | 2-methylene-1alpha,25-dihydroxy-19,21-dinorvitamin D3 analogs and uses thereof | |
| ES2223642T3 (es) | Analogos de la vitamina d. | |
| CA2544501A1 (en) | Vitamin d receptor modulators | |
| CA2506891A1 (en) | Vitamin d receptor modulators | |
| CA2544517A1 (en) | Vitamin d receptor modulators | |
| CA2488334C (en) | 24-sulfoximine vitamin d3 compounds | |
| JP2007512326A5 (https=) | ||
| DE69714590T2 (de) | Vitamin d analoge verbindungen | |
| EP0450743A1 (de) | 24-Oxa-Derivate in der Vitamin D-Reihe | |
| CA2588396C (en) | 17,20(e)-dehydro vitamin d analogs and their uses | |
| CA2605727A1 (en) | 19,26,27-trinor-1.alpha.,25-dihydroxyvitamin d3 compounds | |
| AU2012262174B2 (en) | (22E)-2-methylene-26,27-cyclo-22-dehydro-1alpha-hydroxy-19-norvitamin D3 derivatives | |
| CA2646911A1 (en) | 2- substituted-1alpha, 25-dihydroxy-19,26,27-trinor vitamin d analogs and uses thereof | |
| AU2006230296B2 (en) | 2-methylene-19-nor-(23s)-25-dehydro-1alpha-hydroxyvitamin D3-26,23-lactone and 2-methylene-19-nor-(23R)-25-dehydro-1alpha-hydroxyvitamin D3-26,23-lactone | |
| AU2009268508A1 (en) | 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs | |
| US20110294764A1 (en) | 2-METHYLENE-19,26-NOR-(20S)-1alpha-HYDROXYVITAMIN D3 | |
| RU2013124033A (ru) | Производное 23-ин-витамина d3 | |
| AU2011232562B2 (en) | Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25- dihydroxyvitamin D3 | |
| Chodynski et al. | Synthesis of side-chain homologated analogs of 1, 25-dihydroxycholecalciferol and 1, 25-dihydroxyergocalciferol | |
| DE69406183T2 (de) | Jodvitamin-D-Verbindungen und Verfahren zu ihrer Herstellung | |
| Watanabe et al. | Synthesis of tritiated 1α, 25‐dihydroxy‐2β‐(3‐hydroxypropoxy) vitamin D3 (ED‐71) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20130402 |